尽管并发症发生率相对较高，但内镜乳头切除术（EP）被推荐作为壶腹肿瘤的一线治疗方法。胰腺和/或胆道支架的放置由内窥镜医师自行决定，以预防 EP 后并发症。本研究旨在评估不同支架的疗效。共有117名2006年6月至2022年10月期间接受EP且符合标准的患者纳入该研究。这些患者被分为胰腺支架组（PS 组，n = 47）、胆道支架组（BS 组，n = 38）和双支架组（PBS [PS 和 BS] 组，n = 32） 。收集并比较三组的相关临床资料。采用多因素logistic分析探讨EP后并发症的危险因素。所有并发症的发生率为37.6%（44/117）。胰腺炎和出血是两种最常见的并发症，发生率分别为14.5%（17/117）和17.9%（21/117）。 PS组、BS组、PBS组EP后胰腺炎发生率分别为10.6%（5/47）、23.7%（9/38）、9.4%（3/32），差异无统计学意义。差异。三组之间其他并发症也没有显着差异。年龄（比值比 [OR]：0.95；95% 置信区间 [CI]：0.91-0.99；P = 0.022）与 EP 后胰腺炎独立相关，而肿瘤大小（OR：1.66；95% CI：1.06-2.60；95% CI：1.06-2.60）与 EP 后胰腺炎独立相关。 P = 0.028）与EP后出血独立相关。虽然胰腺支架置入术是预防EP后胰腺炎的首选，但胆道支架置入术也可以被考虑作为胰腺插管困难患者的替代方案。除非因其他原因需要，否则不需要放置两个支架（胆管和胰腺支架）。版权所有 © 2024 The Chinese Medical Association，由 Wolters Kluwer, Inc. 根据 CC-BY-NC-ND 许可制作。

Endoscopic papillectomy (EP) is recommended as the first-line therapy for ampullary tumors, despite a relatively high incidence of complications. Pancreatic and/or biliary stents are placed at the endoscopist's discretion to prevent post-EP complications. The present study aimed to evaluate the efficacy of different stents.A total of 117 patients who underwent EP and met the criteria between June 2006 and October 2022 were enrolled in the study. These patients were divided into a pancreatic stent group (PS group, n = 47), a biliary stent group (BS group, n = 38), and a two-stent group (PBS [PS and BS] group, n = 32). Relevant clinical data were collected and compared among the three groups. Multivariate logistic analyses were performed to explore risk factors for post-EP complications.The incidence of all complications was 37.6% (44/117). Pancreatitis and hemorrhage were the two most common complications with incidence rates of 14.5% (17/117) and 17.9% (21/117). The incidence rates of post-EP pancreatitis were 10.6% (5/47), 23.7% (9/38), and 9.4% (3/32) in the PS group, BS group, and PBS group, respectively, with no significant differences. There were also no significant differences in other complications among the three groups. Age (odds ratio [OR]: 0.95; 95% confidence interval [CI]: 0.91-0.99; P = 0.022) was independently associated with post-EP pancreatitis while tumor size (OR: 1.66; 95% CI: 1.06-2.60; P = 0.028) was independently associated with post-EP hemorrhage.While pancreatic stenting is the first choice to prevent post-EP pancreatitis, biliary stenting could also be considered as a substitute for patients with difficulties in pancreatic cannulation. Two-stent (biliary and pancreatic stent) placement is unnecessary unless it is required due to other concerns.Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.